Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2012 Aug;67(8):754-6.
doi: 10.1136/thoraxjnl-2012-201869. Epub 2012 May 11.

Clinical management and outcome of refractory asthma in the UK from the British Thoracic Society Difficult Asthma Registry

Joan Sweeney  1 , Chris E Brightling, Andrew Menzies-Gow, Robert Niven, Chris C Patterson, Liam G Heaney; British Thoracic Society Difficult Asthma Network
Affiliations
Multicenter Study

Clinical management and outcome of refractory asthma in the UK from the British Thoracic Society Difficult Asthma Registry

Joan Sweeney et al. Thorax. 2012 Aug.

Abstract

Refractory asthma represents a significant unmet clinical need. Data from a national online registry audited clinical outcome in 349 adults with refractory asthma from four UK specialist centres in the British Thoracic Society Difficult Asthma Network. At follow-up, lung function improved, with a reduction in important healthcare outcomes, specifically hospital admission, unscheduled healthcare visits and rescue courses of oral steroids. The most frequent therapeutic intervention was maintenance oral corticosteroids and most steroid sparing agents (apart from omalizumab) demonstrated minimal steroid sparing benefit. A significant unmet clinical need remains in this group, specifically a requirement for therapies which reduce systemic steroid exposure.

PubMed Disclaimer

Conflict of interest statement

Competing interests: Ms Sweeney is supported by HSC R&D (NI) and GlaxoSmithKline (PhD studentship funding). Professor Brightling is supported by a Wellcome Senior Clinical Fellowship and has received consultancy fees and or research funding from GlaxoSmithKline, AZ, MedImmune, Amgen, Novartis, Chiesi, BI and Roche. Dr Menzies-Gow has attended advisory boards for Novartis and Genentech. He has received sponsorship to attend international meetings from GlaxoSmithKline, Novartis and Boeringer Ingelheim. He has received lecture fees from Novartis, GlaxoSmithKline, Astra Zeneca and Chiesi. Dr Niven has received an unrestricted grant of £10 000 from Novartis in 2010 towards development of clinical services at the University Hospital of South Manchester. In addition he has lectured in the field of severe allergic asthma at Novartis-sponsored meetings receiving honoraria in total not exceeding £5000 in the last 3 years. Dr Niven has also performed lecturing at pharmaceutically sponsored meetings for the following pharmaceutical companies in the last 3 years: Astra Zeneca (<£1000), GlaxoSmithKline (<£5000) and Chiesi (<£1000). He has sat on advisory boards for the following companies in the last 3 years: Vectura, Novartis, GlaxoSmithKline, receiving reimbursement not exceeding £1000. He has received sponsorship support to attend international academic meetings. Dr Niven (or any members of his family) has no shares or any percuniary interest in any pharmaceutical industry and has nothing to gain financially from the publication of this paper. Dr C Patterson's spouse holds shares in GlaxoSmithKline. Professor Heaney has received grant funding from Genentech, and GlaxoSmithKline, has taken part in Advisory Boards and given lectures at meetings supported by GlaxoSmithKline, Merck Sharpe & Dohme, Nycomed, Novartis and Astra Zeneca. He has received support funding to attend International Respiratory meetings (Astra Zeneca, Chiesi, Novartis, Teva and GlaxoSmithKline) and has taken part in asthma clinical trials (GSK and Genentech) for which his Institution was remunerated. None of these activities have any direct relationship to the content of this manuscript.

References

    1. Heaney LG, Brightling CE, Menzies-Gow A, et al. Refractory asthma in the UK: cross sectional findings from a UK multicentre registry. Thorax 2010;65:787–94 - PMC - PubMed
    1. Petsky HL, Cates CJ, Lasserson TJ, et al. A systematic review and meta-anslysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). Thorax 2012;67:199–208 - PubMed
    1. Hashimoto S, Brinke AT, Roldaan AC, et al. Internet-based tapering of oral corticosteroids in severe asthma: a pragmatic randomised controlled trial. Thorax 2011;66:514–20 - PubMed
    1. Heaney LG, Conway E, Kelly C, et al. Predictors of therapy resistant asthma: outcome of a systematic evaluation protocol. Thorax 2003;58:561–6 - PMC - PubMed
    1. Moore WC, Bleecker ER, Curran-Everett D, et al. ; For the National Heart, Lung, and Blood Institute's Severe Asthma Research Program Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol 2007;119:405–13 - PMC - PubMed

Publication types

MeSH terms